Gilteritinib Fumarate
A fumarate salt form of gilteritinib, an FLT3 inhibitor used to treat relapsed or refractory acute myeloid leukemia harboring FLT3 mutations. The fumarate salt form is the commercially available formulation used in clinical practice. It selectively targets FLT3-mutated leukemia cells, limiting harm to normal blood cell precursors.
分子量
1221.5000 g/mol
TPSA
317.00 Ų
治疗领域
作用机制
Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.
二维结构
Cite this structure
Embed this structure
SMILES
CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.O=C(O)/C=C/C(=O)O
InChI
InChI=1S/2C29H44N8O3.C4H4O4/c2*1-4-23-28(31-20-9-17-40-18-10-20)34-29(26(33-23)27(30)38)32-21-5-6-24(25(19-21)39-3)37-11-7-22(8-12-37)36-15-13-35(2)14-16-36;5-3(6)1-2-4(7)8/h2*5-6,19-20,22H,4,7-18H2,1-3H3,(H2,30,38)(H2,31,32,34);1-2H,(H,5,6)(H,7,8)/b;;2-1+
Molecular Formula
C62H92N16O10
HBD / HBA
8 / 24
可旋转键数
20
重原子数
88
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
常见问题
A fumarate salt form of gilteritinib, an FLT3 inhibitor used to treat relapsed or refractory acute myeloid leukemia harboring FLT3 mutations. The fumarate salt form is the commercially available formulation used in clinical practice. It selectively targets FLT3-mutated leukemia cells, limiting harm to normal blood cell precursors.
Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.
Yes, Gilteritinib Fumarate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3301603. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 76970819. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="gilteritinib-fumarate"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/gilteritinib-fumarate/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/gilteritinib-fumarate/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/gilteritinib-fumarate/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="gilteritinib-fumarate"></drugfyi-drug>